TITLE

Structural mean models for compliance analysis in randomized clinical trials and the impact of errors on measures of exposure

AUTHOR(S)
Goetghebeur, Els; Vansteelandt, Stijn; Stijn, Vansteelandt
PUB. DATE
August 2005
SOURCE
Statistical Methods in Medical Research;Aug2005, Vol. 14 Issue 4, p397
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Partial compliance with assigned treatment regimes is common in drug trials and calls for a causal analysis of the effect of treatment actually received. As such observed exposure is no longer randomized, selection bias must be carefully accounted for. The framework of potential outcomes allows this by defining a subject-specific treatment-free reference outcome, which may be latent and is modelled in relation to the observed (treated) data. Causal parameters enter these structural models explicitly. In this paper we review recent progress in randomization-based inference for structural mean modelling, from the additive linear model to the structural generalized linear models. An arsenal of tools currently available for standard association regression has steadily been developed in the structural setting, providing many parallel features to help randomization-based inference. We argue that measurement error on exposure is an important practical complication that has, however, not yet been addressed. We show how standard additive linear structural mean models are robust against unbiased measurement error and how efficient, asymptotically unbiased inference can be drawn when the degree of measurement error bias is known. The impact of measurement error is illustrated in a blood pressure example and finite sample properties are verified by simulation. We end with a plea for more and careful use of this methodology and point to directions for further development.
ACCESSION #
17644726

 

Related Articles

  • Calendar of Events.  // Applied Clinical Trials;Jun2004, Vol. 13 Issue 6, p104 

    This article presents information on various events related to clinical trials to be held in several countries. Conference on Project Management for Clinical Trials will be held in Irvine, California on June 1-2, 2004. Conference titled "Monitoring Clinical Drug Studies: Beginner," will be held...

  • The need to consider the wider agenda in systematic reviews and meta-analyses. Ioannidis, John P. A.; Karassa, Fotini B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/9/2010, Vol. 341 Issue 7776, p762 

    This article focuses on the need for systematic reviewers to consider the whole drug research programme for the interventions under study. Two reasons behind the research problem include the testing of the drug for several indications and stopping the first trials early. It argues that the drug...

  • Heart Drug Trial Halted. Hampton, Tracy // JAMA: Journal of the American Medical Association;1/24/2007, Vol. 297 Issue 4, p354 

    The article states that the U.S. Food and Drug Administration has announced that the pharmaceutical company Pfizer Inc. has stopped its phase 3 clinical trial that evaluated an investigational cardiovascular therapy called torcetrapib/atorvastatin. The trial was halted due to an increased rate...

  • Hypothesis to acceptance. Butler, Mike // Pharmaceutical Technology Europe;Feb2009, Vol. 21 Issue 2, p42 

    The author reflects on the methods utilized in clinical trials. He emphasizes the need to filter suitable drug candidates before they enter phase I of a trial to reduce risk of failure. He argues that the use of a microdose approach in Phase 0 of clinical trials can increase the reliability of...

  • Do we learn the right things from clinical trials? Garattini, Silvio; Bertele', Vittorio // European Journal of Clinical Pharmacology;Feb2008, Vol. 64 Issue 2, p115 

    The article presents information about the clinical drug trials. The planning and execution of the trials are the result of innovations which have been introduced into their design over a period of almost 100 years. The trials are classified as phase 1, the aim of which is to form the tolerated...

  • Can ‘phase IV’ work for you? Borfitz, Deborah // Medical Economics;6/6/2003, Vol. 80 Issue 11, p58 

    Focuses on the controversies behind phase IV clinical trials in the U.S. Emphasis on creating a potentiated drug combinations; Collaboration between doctors and pharmaceutical companies to increase drug sales; Quality of drug studies conducted.

  • N.O.'s research facilities prove big draw for clinical drug trials. Kamerick, Megan // New Orleans CityBusiness (1994 to 2008);10/20/2003, Vol. 24 Issue 17, p35 

    Reports on the prevalence of clinical drug trials in New Orleans, Louisiana. Number of trials taking place at the Louisiana State University Health Sciences Center; Impact of the prevalence of clinical trials on the economy of the city; Credibility of academic health science in conducting the...

  • Industry, FDA Warm to "Adaptive" Trials. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;10/25/2006, Vol. 296 Issue 16, p1955 

    The article states that the U.S. Food and Drug Administration has created new guidelines to recognize the trend of pharmaceutical companies evolving their clinical trials while still in progress, based on data achieved through the medical research studies. It is hoped that these adaptive...

  • Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Zipitis, C. S.; Akobeng, A. K. // Archives of Disease in Childhood;Jun2008, Vol. 93 Issue 6, p512 

    Objectives: To assess whether vitamin 0 supplementation in infancy reduces the risk of type 1 diabetes in later life. Methods: This was a systematic review and meta-analysis using Medline, Embase, Cinahl, Cochrane Central Register of Controlled Trials and reference lists of retrieved articles....

  • stronger bones on the cards. Duncan, Debbie // Good Medicine (Australian Consolidated Press);Apr2005, p11 

    Provides an overview of a research being done at the University of Texas Southwestern Medical Center which examines the effectiveness of an injectable drug in reducing bone loss and strengthening the bones.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics